CSIMarket
 


Uniqure N v   (QURE)
Other Ticker:  
 

Cumulative Uniqure N V 's Quick Ratio for Trailing Twelve Months Period

QURE's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

QURE Quick Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth 5.52 % 45.07 % 50.64 % 117.94 % 59.31 %
Y / Y Cash & cash equivalent Growth -47.88 % 2.61 % -70.69 % -59.01 % -23.88 %
Quick Ratio for Trailing Twelve Months Period 4.55 5.47 5.87 8.23 11.95
Total Ranking # 581 # 540 # 579 # 486 # 346
Seq. Current Liabilities Growth 0.24 % 3.25 % -13.13 % 17.37 % 37.8 %
Seq. Cash & cash equivalent Growth -55.32 % 233.83 % -32.53 % -48.22 % -12.03 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to rise in Current Liabilities in the III. Quarter to $61 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 4.55 below Uniqure N V average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 242 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Uniqure N V . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about QURE
Quick Ratio QURE in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 243
Sector # 417
S&P 500 # 619


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
13.79 9.15 4.03
(Mar 31 2022)   (Sep 30 2023)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Bright Minds Biosciences Inc   12.44 
Generation Bio Co   12.38 
Eledon Pharmaceuticals Inc   12.32 
Adicet Bio Inc   12.30 
Atai Life Sciences N v   12.24 
Inhibitor Therapeutics Inc   12.21 
Lianbio  12.20 
Crinetics Pharmaceuticals Inc   12.14 
Cerevel Therapeutics Holdings Inc   11.90 
Xenetic Biosciences Inc   11.68 
Metacrine Inc   11.65 
Caladrius Biosciences Inc   11.53 
Inozyme Pharma Inc   11.53 
Dianthus Therapeutics Inc   11.39 
Cytokinetics Incorporated  11.36 
Trevi Therapeutics Inc   11.34 
Prothena Corporation Public Limited Company  11.24 
Annexon Inc   11.21 
An2 Therapeutics Inc   11.15 
Erasca Inc   11.12 
Reneo Pharmaceuticals Inc   11.07 
Milestone Pharmaceuticals inc   11.06 
Acasti Pharma Inc   10.98 
Sage Therapeutics Inc   10.78 
Biomea Fusion Inc   10.74 
Relmada Therapeutics Inc   10.64 
Cogent Biosciences Inc   10.43 
Sinovac Biotech Ltd  10.37 
Point Biopharma Global Inc   10.33 
Kalvista Pharmaceuticals Inc   10.31 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com